Cyclo Therapeutics to Present at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2024
Cyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC™ Trial of Niemann-Pick Type C1
Cyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
Cyclo Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo
Cyclo Announces Allowance of Patent Application for Alzheimer’s Disease
Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.
Cyclo Announces Outcome from Meeting with FDA Discussing Trappsol Cyclo Program
Cyclo Therapeutics to Present at the 20th Annual WORLDSymposium™ 2024
Cyclo Therapeutics Reports Third Quarter 2023 Financial Results